Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
Open Access
- 1 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (1), 160-169
- https://doi.org/10.1158/1535-7163.mct-05-0199
Abstract
The activity and stability of the p53 tumor suppressor are regulated by the human homologue of the mouse double minute 2 (Hdm2) oncoprotein. It has been hypothesized that small molecules disrupting the Hdm2:p53 complex would allow for the activation of p53 and result in growth suppression. We have identified small-molecule inhibitors of the Hdm2:p53 interaction using our proprietary ThermoFluor microcalorimetry technology. Medicinal chemistry and structure-based drug design led to the development of an optimized series of benzodiazepinediones, including TDP521252 and TDP665759. Activities were dependent on the expression of wild-type (wt) p53 and Hdm2 as determined by lack of potency in mutant or null p53-expressing cell lines or cells engineered to no longer express Hdm2 and wt p53. TDP521252 and TDP665759 inhibited the proliferation of wt p53-expressing cell lines with average IC50s of 14 and 0.7 μmol/L, respectively. These results correlated with the direct cellular dissociation of Hdm2 from wt p53 observed within 15 minutes in JAR choriocarcinoma cells. Additional activities of these inhibitors in vitro include stabilization of p53 protein levels, up-regulation of p53 target genes in a DNA damage–independent manner, and induction of apoptosis in HepG2 cells. Administration of TDP665759 to mice led to an increase in p21waf1/cip1 levels in liver samples. Finally, TDP665759 synergizes with doxorubicin both in culture and in an A375 xenograft model to decrease tumor growth. Taken together, these data support the potential utility of small-molecule inhibitors of the Hdm2:p53 interaction for the treatment of wt p53-expressing tumors. [Mol Cancer Ther 2006;5(1):160–9]Keywords
This publication has 57 references indexed in Scilit:
- Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xLMolecular Cancer Therapeutics, 2005
- Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in CellsJournal of Medicinal Chemistry, 2005
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- China approves first gene therapyNature Biotechnology, 2004
- Chromium (VI) Activates Ataxia Telangiectasia Mutated (ATM) ProteinPublished by Elsevier BV ,2003
- Requirement for HDM2 Activity in the Rapid Degradation of p53 in NeuroblastomaPublished by Elsevier BV ,2001
- Role of MDM2 Overexpression in Doxorubicin Resistance of Breast CarcinomaJapanese Journal of Cancer Research, 1998
- The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivoOncogene, 1997
- Molecular characterization of the hdm2-p53 interactionJournal of Molecular Biology, 1997
- p53 phosphorylation: Biochemical and functional consequencesLife Sciences, 1996